<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47019">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02052427</url>
  </required_header>
  <id_info>
    <org_study_id>ATHENA II</org_study_id>
    <nct_id>NCT02052427</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)</brief_title>
  <acronym>ATHENA II</acronym>
  <official_title>Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, placebo-controlled, double blind safety and  efficacy
      clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and efficacy of Adipose-Derived Regenerative Cells (ADRCs) delivered
      via an intramyocardial route in the treatment of chronic ischemic heart disease in patients
      who are not eligible for percutaneous or surgical revascularization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Efficacy - Change in Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>6 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Minnesota Living with Heart Failure Questionnaire prior to treatment and at 6 months post treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy - Change in mVO2</measure>
    <time_frame>6 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in mVO2 at 6 months as assessed by Exercise Tolerance Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy - Change in LVESV/LVEDV</measure>
    <time_frame>6 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in LVESV/LVEDV at 6 months as assessed by Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy - Change in Ejection Fraction</measure>
    <time_frame>6 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Ejection Fraction (%) at 6 months assessed by 2D Contrast Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy - Change in perfusion defect</measure>
    <time_frame>6 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in perfusion defect at 6 months assessed by Rest/Pharmacologic Stress SPECT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy - Resource Utilization</measure>
    <time_frame>through 12 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resource utilization - hospital length of stay, re-hospitalization for cardiac related events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy - Change in heart failure symptoms, angina, and quality of life</measure>
    <time_frame>through 12 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in heart failure symptoms, angina, and quality of life assessed by - NYHA classification, CCS classification, MLHFQ (other than 6 months)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety - Number of Patients Experiencing Treatment Emergent SAEs</measure>
    <time_frame>Treatment through 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Safety - Number of Patients Experiencing Arrhythmias Assessed via Holter monitor</measure>
    <time_frame>Screening through 3 months post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Safety - Number of patients that experience a MACE</measure>
    <time_frame>Treatment through 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients that experience a Major Adverse Cardiac Event (MACE)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Adipose-Derived Regenerative Cells (ADRCs) - Celution System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adipose-Derived Regenerative Cells (ADRCs) processed by the Celution System:
0.8 x 10^6 cells/kg body weight (not to exceed 80.0 x 10^6 cells)
Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Physiological Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - Physiological Solution
Inactive substance (Lactated Ringers + autologous blood)
Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adipose-Derived Regenerative Cells (ADRCs) - Celution System</intervention_name>
    <description>ADRCs processed by the Celution System for reintroduction into the myocardium</description>
    <arm_group_label>Adipose-Derived Regenerative Cells (ADRCs) - Celution System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo - Physiological Solution</intervention_name>
    <description>Physiological solution made of Lactated Ringers solution and a small amount (&lt;1mL) of autologous blood</description>
    <arm_group_label>Placebo - Physiological Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females &gt; 20 and &lt; 80 years of age

          2. Significant multi-vessel coronary artery disease not amenable to percutaneous or
             surgical revascularization

          3. CCS Angina Functional Class II-IV and/or NYHA Stages of Heart Failure Class II or III

          4. On maximal medical therapy for anginal symptoms and/or heart failure symptoms

          5. Hemodynamic stability (SBP ≥ 90 mm/Hg, HR &lt;110)

          6. Ejection fraction ≥ 20% and ≤ 45%

          7. Inducible ischemia using an objective assessment of ischemia within 1 year of
             screening (i.e. exercise ECG changes, SPECT)

          8. Left ventricular wall thickness ≥ 8 mm at the target site for cell injection

        Exclusion Criteria:

          1. Atrial fibrillation or flutter without a pace maker that guarantees a stable heart
             rate

          2. Unstable angina

          3. LV thrombus, as documented by echocardiography

          4. Planned staged treatment of CAD or other intervention on the heart

          5. Platelet count &lt; 100,000/mm3

          6. WBC &lt; 2,000/mm3

          7. TIA or stroke within 90 days prior to randomization

          8. ICD shock within 30 days prior to randomization

          9. Any condition requiring immunosuppressive medication

         10. A high-risk acute coronary syndrome (ACS) or a myocardial infarction in the 60 days
             prior to randomization

         11. Revascularization within 60 days prior to randomization

         12. Inability to walk on a treadmill except for class IV angina patients who will be
             evaluated separately

         13. Hepatic dysfunction, as defined as aspartate aminotransferase (AST) and/or alanine
             aminotransferase (ALT) &gt; 1.5 times the upper limit of normal range (x ULN)

         14. Hemoglobin ≤ 10.0 g/dL
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emerson C. Perin, MD, PhD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Stem Cell Center at Texas Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eve Taylor, PhD</last_name>
    <phone>858.458.0900</phone>
    <phone_ext>5239</phone_ext>
    <email>etaylor@cytori.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rhiannon Dabkowski, BS</last_name>
    <phone>858-458-0900</phone>
    <phone_ext>5297</phone_ext>
    <email>rdabkowski@cytori.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>11100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Mazzurco, RN, BSN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic heart disease</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>adult stem cells</keyword>
  <keyword>adipose derived regenerative cells</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
